Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
AMS vs IART vs NVCR vs ATRC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
AMS vs IART vs NVCR vs ATRC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $13M | $1.06B | $1.92B | $1.41B |
| Revenue (TTM) | $29M | $1.64B | $674M | $552M |
| Net Income (TTM) | $-2M | $-496M | $-173M | $-5M |
| Gross Margin | 25.0% | 39.6% | 75.2% | 75.5% |
| Operating Margin | -12.3% | 5.8% | -27.2% | -0.4% |
| Forward P/E | 6.1x | 5.7x | — | 428.7x |
| Total Debt | $23M | $2.03B | $290M | $88M |
| Cash & Equiv. | $11M | $235M | $103M | $167M |
AMS vs IART vs NVCR vs ATRC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| American Shared Hos… (AMS) | 100 | 110.3 | +10.3% |
| Integra LifeScience… (IART) | 100 | 26.7 | -73.3% |
| NovoCure Limited (NVCR) | 100 | 26.5 | -73.5% |
| AtriCure, Inc. (ATRC) | 100 | 55.0 | -45.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMS vs IART vs NVCR vs ATRC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMS is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta -0.02
- Rev growth 32.9%, EPS growth 245.9%, 3Y rev CAGR 17.1%
- 32.9% revenue growth vs IART's 1.5%
IART is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (5.7x vs 428.7x)
- +6.5% vs AMS's -27.4%
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
ATRC carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 95.1% 10Y total return vs AMS's -4.7%
- Lower volatility, beta 1.03, Low D/E 17.9%, current ratio 3.96x
- Beta 1.03, current ratio 3.96x
- -0.8% margin vs IART's -30.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs IART's 1.5% | |
| Value | Lower P/E (5.7x vs 428.7x) | |
| Quality / Margins | -0.8% margin vs IART's -30.1% | |
| Stability / Safety | Beta 1.03 vs IART's 2.34, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +6.5% vs AMS's -27.4% | |
| Efficiency (ROA) | -0.7% ROA vs NVCR's -16.5%, ROIC -0.6% vs -16.4% |
AMS vs IART vs NVCR vs ATRC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMS vs IART vs NVCR vs ATRC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ATRC leads in 2 of 6 categories
AMS leads 2 • IART leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ATRC leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IART is the larger business by revenue, generating $1.6B annually — 55.9x AMS's $29M. ATRC is the more profitable business, keeping -0.8% of every revenue dollar as net income compared to IART's -30.1%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $29M | $1.6B | $674M | $552M |
| EBITDAEarnings before interest/tax | $2M | $209M | -$165M | $13M |
| Net IncomeAfter-tax profit | -$2M | -$496M | -$173M | -$5M |
| Free Cash FlowCash after capex | -$10M | -$10M | -$48M | $54M |
| Gross MarginGross profit ÷ Revenue | +25.0% | +39.6% | +75.2% | +75.5% |
| Operating MarginEBIT ÷ Revenue | -12.3% | +5.8% | -27.2% | -0.4% |
| Net MarginNet income ÷ Revenue | -7.6% | -30.1% | -25.7% | -0.8% |
| FCF MarginFCF ÷ Revenue | -34.7% | -0.6% | -7.1% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +2.4% | +12.3% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.7% | +81.8% | -100.0% | +101.6% |
Valuation Metrics
AMS leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMS's 7.5x EV/EBITDA is more attractive than ATRC's 77.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $13M | $1.1B | $1.9B | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $25M | $2.9B | $2.1B | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | 6.09x | -2.01x | -13.80x | -115.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.71x | — | 428.71x |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — |
| EV / EBITDAEnterprise value multiple | 7.51x | 13.01x | — | 77.75x |
| Price / SalesMarket cap ÷ Revenue | 0.46x | 0.65x | 2.92x | 2.63x |
| Price / BookPrice ÷ Book value/share | 0.45x | 1.00x | 5.51x | 2.70x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 29.15x |
Profitability & Efficiency
ATRC leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ATRC delivers a -1.0% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-51 for NVCR. ATRC carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to IART's 1.95x.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.9% | -47.6% | -50.8% | -1.0% |
| ROA (TTM)Return on assets | -3.8% | -13.7% | -16.5% | -0.7% |
| ROICReturn on invested capital | -5.8% | +1.7% | -16.4% | -0.6% |
| ROCEReturn on capital employed | -6.4% | +2.2% | -28.9% | -0.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.77x | 1.95x | 0.85x | 0.18x |
| Net DebtTotal debt minus cash | $12M | $1.8B | $187M | -$79M |
| Cash & Equiv.Liquid assets | $11M | $235M | $103M | $167M |
| Total DebtShort + long-term debt | $23M | $2.0B | $290M | $88M |
| Interest CoverageEBIT ÷ Interest expense | -1.35x | -10.36x | -96.80x | 0.47x |
Total Returns (Dividends Reinvested)
AMS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMS five years ago would be worth $5,894 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, IART leads with a +6.5% total return vs AMS's -27.4%. The 3-year compound annual growth rate (CAGR) favors AMS at -10.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -4.3% | +12.9% | +28.3% | -29.2% |
| 1-Year ReturnPast 12 months | -27.4% | +6.5% | +1.1% | -8.3% |
| 3-Year ReturnCumulative with dividends | -28.0% | -73.1% | -75.7% | -41.8% |
| 5-Year ReturnCumulative with dividends | -41.1% | -81.7% | -91.3% | -64.2% |
| 10-Year ReturnCumulative with dividends | -4.7% | -63.0% | +30.3% | +95.1% |
| CAGR (3Y)Annualised 3-year return | -10.4% | -35.4% | -37.6% | -16.5% |
Risk & Volatility
Evenly matched — AMS and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
AMS is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than IART's 2.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs ATRC's 64.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.07x | 2.39x | 2.15x | 0.95x |
| 52-Week HighHighest price in past year | $3.11 | $16.49 | $20.06 | $43.18 |
| 52-Week LowLowest price in past year | $1.25 | $8.70 | $9.82 | $26.62 |
| % of 52W HighCurrent price vs 52-week peak | +64.6% | +82.2% | +83.9% | +64.4% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 75.9 | 69.8 | 45.0 |
| Avg Volume (50D)Average daily shares traded | 138K | 858K | 1.5M | 669K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IART as "Buy", NVCR as "Buy", ATRC as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -11.5% for IART (target: $12).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $12.00 | $33.50 | $51.33 |
| # AnalystsCovering analysts | — | 26 | 15 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% | 0.0% | +0.8% |
ATRC leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMS leads in 2 (Valuation Metrics, Total Returns). 1 tied.
AMS vs IART vs NVCR vs ATRC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMS or IART or NVCR or ATRC a better buy right now?
For growth investors, American Shared Hospital Services (AMS) is the stronger pick with 32.
9% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). American Shared Hospital Services (AMS) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate Integra LifeSciences Holdings Corporation (IART) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMS or IART or NVCR or ATRC?
On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5.
7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AMS or IART or NVCR or ATRC?
Over the past 5 years, American Shared Hospital Services (AMS) delivered a total return of -41.
1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ATRC returned +84. 4% versus IART's -62. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMS or IART or NVCR or ATRC?
By beta (market sensitivity over 5 years), American Shared Hospital Services (AMS) is the lower-risk stock at -0.
07β versus Integra LifeSciences Holdings Corporation's 2. 39β — meaning IART is approximately -3640% more volatile than AMS relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — AMS or IART or NVCR or ATRC?
By revenue growth (latest reported year), American Shared Hospital Services (AMS) is pulling ahead at 32.
9% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: American Shared Hospital Services grew EPS 245. 9% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMS or IART or NVCR or ATRC?
American Shared Hospital Services (AMS) is the more profitable company, earning 7.
7% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IART leads at 4. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMS or IART or NVCR or ATRC more undervalued right now?
On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.
7x forward P/E versus 428. 7x for AtriCure, Inc. — 423. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — AMS or IART or NVCR or ATRC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AMS or IART or NVCR or ATRC better for a retirement portfolio?
For long-horizon retirement investors, American Shared Hospital Services (AMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
07)). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 39 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMS: -3. 8%, IART: -62. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMS and IART and NVCR and ATRC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AMS is a small-cap high-growth stock; IART is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.